Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

Bempedoic Acid Gains CV Risk Reduction Indication

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

March 22, 2024

FDA Approves Colchicine for Decreasing CV Events

News Daily News

FDA Approves Colchicine for Decreasing CV Events

June 20, 2023

TCTMD’s Top 10 Most Popular Stories for December 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

December 29, 2021

British Medical Groups Express Concern About Inclisiran Rollout

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

FDA Approves Evinacumab for Rare Homozygous FH

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

Inclisiran Approved in Europe for Lowering LDL Cholesterol

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

February 26, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.